Navigation Links
Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules
Date:5/18/2012

BETHLEHEM, Pa., May 18, 2012 /PRNewswire/ -- Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE™, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.    

PERTZYE is a unique pancreatic enzyme product containing bicarbonate-buffered enteric-coated microspheres and is protected by several U.S. and international patents.  The PERTZYE formulation was previously marketed by DCI for over a decade under the trade name PANCRECARB® MS-16. 

Dr. Tibor Sipos, President and Chief Scientific Officer at DCI stated, "The approval of PERTZYE represents a significant milestone for DCI.  This achievement confirms our commitment to the continued development of products vital to the well-being of patients living with chronic diseases."

The short-term safety and efficacy of PERTZYE were evaluated in a randomized, multicenter, double-blind, placebo-controlled, crossover study conducted in patients ages 8 to 43 years with EPI due to CF.(1)  The primary efficacy endpoint was the mean difference in coefficient of fat absorption (CFA) between PERTZYE and placebo treatment.  Mean CFA was 83% with PERTZYE treatment compared to 46% with placebo treatment (p<0.001).  For complete safety information, warnings, precautions and limitations of use for PERTZYE, please see the full Prescribing Information and Medication Guide available at www.digestivecare.com.

"The improvement in mean CFA observed in the controlled study represents a clinically meaningful treatment benefit for patients using PERTZYE.  Availability of this unique buffered formulation of pancreatic enzyme is an important addition to the therapeutic options for CF and other patients with EPI," stated Michael W. Konstan, MD, Chairman of Pediatrics, Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio.

Additional information on the approval of PERTZYE can be found in the FDA Updated Questions and Answers for Healthcare Professionals and the Public: Use an Approved Pancreatic Enzyme Product (PEP) at

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204745.htm.

About Digestive Care, Inc.

DCI is a fully integrated pharmaceutical company, founded in 1990, dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders.  For further information, please visit us at www.digestivecare.com

References

1. MW Konstan, SD Strausbaugh, RC Ahrens, FJ Accurso, GR Graff, SZ Nasr.  Pediatric Pulmonology Suppl 31:425, 2008.


'/>"/>
SOURCE Digestive Care, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
2. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
3. UCB Proudly Reinforces Long-Standing Commitment to Crohns Disease Community at Digestive Disease Week 2012
4. Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterologys 76th Annual Meeting
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Voices of UC Survey Shows Need for Patients with Ulcerative Colitis to Speak Up about Debilitating Digestive Disease
7. WellSpring Pharmaceutical, American Gastroenterological Association, and Steven Bramson of Humanscale Partner With MediaPlanet to Publish One of the Largest Digestive Wellness Campaigns in U.S. History to Overcome Upset Stomach, Nausea, IBS, and Deb
8. Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
11. Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... in the U.S. and Europe , announced ... laser at the upcoming 151 st Midwinter Meeting of ... #4815. The ST PRO is a full featured hard and ... the award winning, industry leading Lightwalker ATS. At an introductory price ... attractive to many dentists hesitating to incorporate lasers into their ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... as the World Molecular Imaging Congress (WMIC), will be held in New York ... meeting is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC ... of medical professionals throughout the country. The Guard was specifically designed to handle ... procedures, employee training, regulatory updates, and compliance coaching. , In addition to meeting ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Dr. Jessica Barron, ... practice is now accepting new dental patients and families in the North Metro Denver ... care services from cleanings to cosmetic dentistry, and all in the most relaxing environment. ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the ... ended December 31, 2015 on Monday, February 29, 2016 after the market closes. , ... the release at 4:30 PM ET. Investors interested in participating by phone are invited ...
Breaking Medicine News(10 mins):